Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.46 |
| ▸ | SMPD3 | Q9NY59 | 5/20 | 0.43 |
| ▸ | RET | P07949 | 2/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | SPR | P35270 | 3/20 | 0.39 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.38 |
| ▸ | ITGAL | P20701 | 1/20 | 0.38 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19466781 | 0.89 | SMPD3 (0.48) | AAK1SMPD3FYNITGB2ICAM1 | |
| SCHEMBL29660251 | 0.89 | AAK1 (0.51) | AAK1PDE10ASMPD3FYNITGB2 | |
| SCHEMBL19467059 | 0.85 | AAK1 (0.46) | AAK1SMPD3FYNITGB2ICAM1 | |
| SCHEMBL19467060 | 0.85 | AAK1 (0.46) | AAK1SMPD3FYNITGB2ICAM1 | |
| SCHEMBL30102999 | 0.85 | AAK1 (0.45) | AAK1SMPD3FYNITGB2ICAM1 | |
| SCHEMBL19467271 | 0.85 | AAK1 (0.45) | AAK1SMPD3FYNITGB2ICAM1 | |
| SCHEMBL19466940 | 0.85 | AAK1 (0.50) | AAK1PDE10ASMPD3RETSPR | |
| SCHEMBL19466939 | 0.85 | AAK1 (0.50) | AAK1PDE10ASMPD3RETSPR | |
| SCHEMBL19467270 | 0.85 | AAK1 (0.45) | AAK1SMPD3FYNITGB2ICAM1 | |
| SCHEMBL29660248 | 0.81 | AAK1 (0.57) | AAK1PDE10ASMPD3RETSPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677705-A | AAK1 inhibitor and application thereof | 武汉人福创新药物研发中心有限公司 | 2023-02-03 | — | — | CN | claimed |
| US-11666575-B2 | Pyrazolo[1,5]pyrimidine-based compounds and methods of their use to treat viral infections | LEXICON PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| CN-115677705-A | AAK1 inhibitor and application thereof | 武汉人福创新药物研发中心有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115427045-A | 4- (3- (pyridin-3-yl) pyrazolo [1,5-a ] pyrimidin-5-yl) piperazine for the treatment of COV-229E or COV-OC43 coronavirus infection | 莱西肯医药有限公司 | 2022-12-02 | — | — | CN | disclosed |
| US-20220096481-A1 | PYRAZOLO[1,5]PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE TO TREAT VIRAL INFECTIONS | OXFORD FINANCE LLC | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666575-B2 | Pyrazolo[1,5]pyrimidine-based compounds and methods of their use to treat viral infections | IRAK1, SARS1, IRAK2 | AAK1 4/4885PDE10A 4249/4885SMPD3 3682/4885 |
| US-20220096481-A1 | PYRAZOLO[1,5]PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE TO TREAT VIRAL INFECTIONS | IRAK1, SARS1, IRAK2 | AAK1 4/4885PDE10A 4249/4885SMPD3 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.